Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | Lapatinib | 0.01 | uM | 9 | 625.00 | 414.82 | 755.00 | 795.25 | 0.9494 | 0.8924 |
SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 625.00 | 414.82 | 529.00 | 795.25 | 0.6652 | 0.2956 |
SK-BR-3 | 17-AAG | 0.31623 | uM | 9 | 625.00 | 414.82 | 385.00 | 795.25 | 0.4841 | -0.0764 |
SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 625.00 | 414.82 | 944.00 | 795.25 | 1.1870 | 1.4007 |
SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 910.00 | 795.25 | 1.1443 | 1.3087 | |
SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 625.00 | 414.82 | 531.00 | 795.25 | 0.6677 | 0.3008 |
SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 625.00 | 414.82 | 701.00 | 795.25 | 0.8815 | 0.7486 |
SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 625.00 | 414.82 | 867.00 | 795.25 | 1.0902 | 1.1927 |
SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 625.00 | 414.82 | 447.00 | 795.25 | 0.5621 | 0.0828 |
SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 746.00 | 795.25 | 0.9381 | 0.8684 | |
SK-BR-3 | 0 | uM | 9 | 1250.00 | 830.55 | 1781.00 | 2071.50 | 0.8598 | 0.7835 | |
SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 1250.00 | 830.55 | 1937.00 | 2071.50 | 0.9351 | 0.9007 |
SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 1250.00 | 830.55 | 1740.00 | 2071.50 | 0.8400 | 0.7522 |
SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 1250.00 | 830.55 | 2122.00 | 2071.50 | 1.0244 | 1.0369 |
SK-BR-3 | Erlotinib | 1 | uM | 9 | 1250.00 | 830.55 | 2075.00 | 2071.50 | 1.0017 | 1.0026 |
SK-BR-3 | Lapatinib | 10 | uM | 9 | 1250.00 | 830.55 | 852.00 | 2071.50 | 0.4113 | 0.0195 |
SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 1250.00 | 830.55 | 2385.00 | 2071.50 | 1.1513 | 1.2256 |
SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 1250.00 | 830.55 | 2303.00 | 2071.50 | 1.1118 | 1.1673 |
SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 1250.00 | 830.55 | 2443.00 | 2071.50 | 1.1793 | 1.2665 |
SK-BR-3 | Lapatinib | 1 | uM | 9 | 1250.00 | 830.55 | 833.00 | 2071.50 | 0.4021 | 0.0022 |
SK-BR-3 | Linsitinib | 10 | uM | 9 | 1250.00 | 830.55 | 1406.00 | 2071.50 | 0.6787 | 0.4907 |
SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 1250.00 | 830.55 | 1675.00 | 2071.50 | 0.8086 | 0.7024 |
SK-BR-3 | Erlotinib | 10 | uM | 9 | 1250.00 | 830.55 | 910.00 | 2071.50 | 0.4393 | 0.0717 |
SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 1250.00 | 830.55 | 2134.00 | 2071.50 | 1.0302 | 1.0456 |
SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 1250.00 | 830.55 | 2478.00 | 2071.50 | 1.1962 | 1.2911 |